Observational studySaudi medical journal2025
Illuminating the role of VEGFA and EGFR in head and neck squamous cell carcinoma through the multi-omics data integration.
Observational study in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tumor Biomarkers in Head and Neck Squamous Cell Carcinoma: From Etiology and Pathogenesis to Treatment Response-A Scoping Review.Biomedicines · 2026Review
- Anlotinib as Third-Line or Later Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Real-World Efficacy and Safety Outcomes.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the functions of 2 crucial wound-healing genes, vascular endothelial growth factor-A (VEGFA) and epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinoma (HNSCC).
methodsThis observational study, carried out between January and August 2024 in Saudi Arabia, involved 20 HNSCC and 10 normal oral cell lines sourced from The American type culture collection. Cell lines were cultured and gene expression was analyzed via RT-qPCR and Western blotting. Promoter methylation and mutational analyses were carried out using databases like UALCAN and cBioPortal. Functional assays, including cell proliferation, colony formation, and wound healing, were carried out to evaluate the effects of VEGFA and EGFR gene silencing using siRNA.
resultsExpression analysis of 20 HNSCC cell lines showed significant upregulation of VEGFA and EGFR, confirming their potential as biomarkers. Receiver operating characteristic curve analysis further supported their discriminatory capabilities. Promoter methylation analysis revealed hypomethylation of both genes in HNSCC. Validation confirmed elevated mRNA and protein expression, especially in advanced stages. Mutational analysis indicated infrequent mutations. A prognostic model showed a correlation between higher VEGFA and EGFR expression and reduced overall survival. Knockdown experiments in human oral squamous carcinoma-3 cells reduced growth, and DrugBank identified Simvastatin as a potential therapeutic, with molecular docking showing strong interactions.
conclusionThis study highlights VEGFA and EGFR as diagnostic, prognostic, and therapeutic targets in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.